Cite
Ruxolitinib inhibits poly(I:C) and type 2 cytokines‐induced CCL5 production in bronchial epithelial cells: A potential therapeutic agent for severe eosinophilic asthma.
MLA
Sada, Mitsuru, et al. “Ruxolitinib Inhibits Poly(I:C) and Type 2 Cytokines‐induced CCL5 Production in Bronchial Epithelial Cells: A Potential Therapeutic Agent for Severe Eosinophilic Asthma.” Immunity, Inflammation & Disease, vol. 9, no. 2, June 2021, pp. 363–73. EBSCOhost, https://doi.org/10.1002/iid3.397.
APA
Sada, M., Watanabe, M., Inui, T., Nakamoto, K., Hirata, A., Nakamura, M., Honda, K., Saraya, T., Kurai, D., Kimura, H., Ishii, H., & Takizawa, H. (2021). Ruxolitinib inhibits poly(I:C) and type 2 cytokines‐induced CCL5 production in bronchial epithelial cells: A potential therapeutic agent for severe eosinophilic asthma. Immunity, Inflammation & Disease, 9(2), 363–373. https://doi.org/10.1002/iid3.397
Chicago
Sada, Mitsuru, Masato Watanabe, Toshiya Inui, Keitaro Nakamoto, Aya Hirata, Masuo Nakamura, Kojiro Honda, et al. 2021. “Ruxolitinib Inhibits Poly(I:C) and Type 2 Cytokines‐induced CCL5 Production in Bronchial Epithelial Cells: A Potential Therapeutic Agent for Severe Eosinophilic Asthma.” Immunity, Inflammation & Disease 9 (2): 363–73. doi:10.1002/iid3.397.